MRD Status in NPM1 Mutated AML Should Be a Part of the Selection of Patients for Transplant in First Remission

Listen to Dr. Jad Othman about his study, presented at the ASH 2023 meeting, which focused on the use of MRD status to determine the necessity of allogeneic stem cell transplant in NPM1 mutated AML patients. Combining data from the UK NCRI AML17 and AML19 studies, the research revealed that MRD negativity after chemotherapy did not warrant a transplant, whereas MRD positive patients benefited significantly. This finding, especially relevant for patients with the FLT3 ITD mutation, underscores the importance of MRD status in making transplant decisions for first remission NPM1 AML patients.